Hiroki Sakoh
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiroki Sakoh.
Chemistry: A European Journal | 1999
Teruaki Mukaiyama; Isamu Shiina; Hayato Iwadare; Masahiro Saitoh; Toshihiro Nishimura; Naoto Ohkawa; Hiroki Sakoh; Koji Nishimura; Yu-ichirou Tani; Masatoshi Hasegawa; Koji Yamada; Katsuyuki Saitoh
A new method for the total asymmetric synthesis of antitumor agent Taxol is described. Baccatin III, a complex carbon framework, is synthesized by way of B to BC to ABC ring construction. Further, a method of forming Taxol from baccatin III and a β-amino acid is also demonstrated.
Current Drug Targets - Infectious Disorders | 2004
Yuichi Sugimoto; Hiroki Sakoh; Koji Yamada
Inositol phosphorylceramide (IPC) synthase is a common and essential enzyme in fungi and plants, which catalyzes the transfer of phosphoinositol to the C-1 hydroxy of ceramide to produce IPC. This reaction is a key step in fungal sphingolipid biosynthesis, therefore the enzyme is a potential target for the development of nontoxic therapeutic antifungal agents. Natural products with a desired biological activity, aureobasidin A (AbA), khafrefungin, and galbonolide A, have been reported. AbA, a cyclic depsipeptide containing 8 amino acids and a hydroxyl acid, is a broad spectrum antifungal with strong activity against many pathogenic fungi such as Candida spp., Cryptococcus neoformans, and some Aspergillus spp. Khafrefungin, an aldonic acid ester with a C22 long alkyl chain, has antifungal activity against C. albicans, Cr. Neoformans, and Saccharomyces cerevisiae. Galbonolide A is a 14-membered macrolide with fungicidal activity against clinically important strains, and is especially potent against Cr. neoformans. These classes of natural products are potent and specific antifungal agents. We review current progress in the development of IPC synthase inhibitors with antifungal activities, and present structure-activity relationships (SAR), physicochemical and structural properties, and synthetic methodology for chemical modification.
Bioorganic & Medicinal Chemistry Letters | 2009
Kensuke Kobayashi; Minaho Uchiyama; Hirokatsu Ito; Hirobumi Takahashi; Takashi Yoshizumi; Hiroki Sakoh; Yasushi Nagatomi; Masanori Asai; Hiroshi Miyazoe; Tomohiro Tsujita; Mioko Hirayama; Satoshi Ozaki; Takeshi Tani; Yasuyuki Ishii; Hisashi Ohta; Osamu Okamoto
The synthesis and biological evaluation of new potent opioid receptor-like 1 antagonists are presented. A structure-activity relationship (SAR) study of arylpyrazole lead compound 1 obtained from library screening identified compound 31, (1S,3R)-N-{[1-(3-chloropyridin-2-yl)-5-(5-fluoro-6-methylpyridin-3-yl)-4-methyl-1H-pyrazol-3-yl]methyl}-3-fluorocyclopentanamine, which exhibits high intrinsic potency and selectivity against other opioid receptors and hERG potassium channel.
Bioorganic & Medicinal Chemistry Letters | 2008
Osamu Okamoto; Kensuke Kobayashi; Hiroshi Kawamoto; Satoru Ito; Atsushi Satoh; Tetsuya Kato; Izumi Yamamoto; Sayaka Mizutani; Masaya Hashimoto; Atsushi Shimizu; Hiroki Sakoh; Yasushi Nagatomi; Yoshikazu Iwasawa; Hiroyuki Takahashi; Yasuyuki Ishii; Satoshi Ozaki; Hisashi Ohta
Structure-activity studies on benzimidazole lead 1 obtained from library screening led to the discovery of potent and selective ORL1 antagonist 28, 5-chloro-2-[(1-ethyl-1-methylpropyl)thio]-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1H-benzimidazole, which is structurally distinct from conventional non-peptide antagonists known to date.
Bioorganic & Medicinal Chemistry | 2002
Hiroki Sato; Hiroki Sakoh; Takashi Hashihayata; Hideaki Imamura; Norikazu Ohtake; Aya Shimizu; Yuichi Sugimoto; Shunji Sakuraba; Rie Bamba-Nagano; Koji Yamada; Terutaka Hashizume; Hajime Morishima
Structure--activity relationship studies of 1beta-methyl-2-[(3S,5R)-5-(4-aminomethylphenyl)pyrrolidin-3-ylthio]carbapenems, especially those pertaining to the relationship between antibacterial activity and side-chain structure were conducted. These studies suggested that the trans-(3S,5R)-5-phenylpyrrolidin-3-ylthio side-chain and the aminomethyl group at the 4-position of the phenyl ring play a key role in enhancing the antibacterial activity against the MRSA and Pseudomonas aeruginosa strains. In particular, the basicity of a substituent at the 4-position of the phenyl ring were shown to greatly contribute to the antibacterial activity against MRSA and methicillin-resistant Staphyloccocus epidermidis strains. In contrast, the amidine group was shown to lead to potent antibacterial activity against P. aeruginosa strains comparable to that of imipenem, however, a good correlation between the basicity of the 4-substituent and antipseudomonal activity was not observed. In conclusion, the 4-aminomethyl or methylaminomethyl group on the phenyl ring was the best substituent for antipseudomonal activity.
Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences | 1997
Teruaki Mukaiyama; Isamu Shiina; Hayato Iwadare; Hiroki Sakoh; Yu-ichirou Tani; Masatoshi Hasegawa; Katsuyuki Saitoh
Chemistry: A European Journal | 1999
Teruaki Mukaiyama; Isamu Shiina; Hayato Iwadare; Masahiro Saitoh; Toshihiro Nishimura; Naoto Ohkawa; Hiroki Sakoh; Koji Nishimura; Yu-ichirou Tani; Masatoshi Hasegawa; Koji Yamada; Katsuyuki Saitoh
Chemistry Letters | 1998
Isamu Shiina; Hayato Iwadare; Hiroki Sakoh; Masatoshi Hasegawa; Yu-ichirou Tani; Teruaki Mukaiyama
Archive | 2006
Masaya Hashimoto; Yoshikazu Banyu Pharmaceutical Co. Ltd. Iwasawa; Hiroshi Kawamoto; Hisashi Ohta; Satoshi Ozaki; Takeshi Sagara; Hiroki Sakoh; Atsushi Satoh
Bioorganic & Medicinal Chemistry Letters | 2004
Hiroki Sakoh; Yuichi Sugimoto; Hideaki Imamura; Shunji Sakuraba; Hideki Jona; Rie Bamba-Nagano; Koji Yamada; Terutaka Hashizume; Hajime Morishima